Detalhe da pesquisa
1.
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Pharmacol Res
; 160: 105058, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32619722
2.
Thyroid follicle development requires Smad1/5- and endothelial cell-dependent basement membrane assembly.
Development
; 143(11): 1958-70, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27068110
3.
Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.
Pharmacol Res
; 129: 337-356, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133216
4.
Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.
Biochem Pharmacol
; 188: 114526, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741332
5.
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia.
Biochem Pharmacol
; 173: 113698, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31706847
6.
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Clin Epigenetics
; 12(1): 69, 2020 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430012